BRCA2 and prostate carcinoma: For instance, prostate cancer with mutations in homologous recombination repair genes such as BRCA1 and BRCA2 shows increased sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors and may benefit from platinum chemotherapy.